Alpha DNA Investment Management LLC Lowers Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)

Alpha DNA Investment Management LLC cut its holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) by 13.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,038 shares of the company’s stock after selling 3,002 shares during the quarter. Alpha DNA Investment Management LLC owned approximately 0.07% of Castle Biosciences worth $436,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Olympiad Research LP purchased a new stake in Castle Biosciences in the fourth quarter worth about $263,000. Vanguard Group Inc. grew its stake in shares of Castle Biosciences by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 1,494,176 shares of the company’s stock worth $33,096,000 after buying an additional 32,695 shares during the last quarter. Acadian Asset Management LLC increased its position in Castle Biosciences by 130.7% during the 1st quarter. Acadian Asset Management LLC now owns 210,824 shares of the company’s stock valued at $4,669,000 after buying an additional 119,443 shares in the last quarter. Bellevue Group AG raised its stake in Castle Biosciences by 0.4% during the fourth quarter. Bellevue Group AG now owns 1,232,378 shares of the company’s stock valued at $26,595,000 after buying an additional 4,347 shares during the last quarter. Finally, Harbor Capital Advisors Inc. boosted its holdings in Castle Biosciences by 249.3% in the second quarter. Harbor Capital Advisors Inc. now owns 138,707 shares of the company’s stock worth $3,020,000 after acquiring an additional 99,001 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Castle Biosciences news, COO Kristen M. Oelschlager sold 2,793 shares of the business’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $22.06, for a total transaction of $61,613.58. Following the completion of the sale, the chief operating officer now directly owns 145,825 shares in the company, valued at approximately $3,216,899.50. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Castle Biosciences news, COO Kristen M. Oelschlager sold 2,793 shares of the business’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $22.06, for a total transaction of $61,613.58. Following the completion of the sale, the chief operating officer now directly owns 145,825 shares in the company, valued at approximately $3,216,899.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Kristen M. Oelschlager sold 12,989 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $23.06, for a total transaction of $299,526.34. Following the sale, the chief operating officer now directly owns 132,836 shares of the company’s stock, valued at approximately $3,063,198.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 33,665 shares of company stock worth $828,222. 7.20% of the stock is owned by insiders.

Castle Biosciences Stock Down 2.2 %

CSTL stock opened at $28.60 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.12 and a quick ratio of 7.92. Castle Biosciences, Inc. has a 1-year low of $12.07 and a 1-year high of $32.53. The stock has a market capitalization of $789.65 million, a P/E ratio of -24.87 and a beta of 1.02. The business has a fifty day moving average price of $26.72 and a 200-day moving average price of $23.40.

Castle Biosciences (NASDAQ:CSTL) last posted its earnings results on Monday, August 5th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.47. Castle Biosciences had a negative net margin of 1.08% and a negative return on equity of 0.77%. The business had revenue of $87.00 million for the quarter, compared to analysts’ expectations of $69.95 million. During the same quarter in the prior year, the business earned ($0.70) EPS. Equities analysts forecast that Castle Biosciences, Inc. will post -0.58 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Robert W. Baird raised their price target on Castle Biosciences from $34.00 to $37.00 and gave the company an “outperform” rating in a report on Tuesday, August 6th. Stephens restated an “overweight” rating and set a $37.00 price objective on shares of Castle Biosciences in a research note on Tuesday, August 6th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Castle Biosciences presently has a consensus rating of “Buy” and a consensus price target of $32.80.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.